AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1506604
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g glucose ingestion in early pregnant women
Trial: 30506745
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (5 g micronized creatine monohydrate daily for three weeks; n=31)
Trial: 26989892
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg arhalofenate
Trial: 26989892
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg arhalofenate
Trial: 18045815
Drug: L-carnitine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (20 mg x kg(‐1))
Trial: 30681802
Drug: Ceramide containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramide containing cleanser and cream with salicylic acid, used twice daily for 28 days.
Trial: 17632223
Drug: bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion SR 300 mg/d + high-dose dual nicotine replacement therapy (NRT) + weekly group cognitive behavioral therapy (CBT)
Trial: 17632223
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + high-dose dual nicotine replacement therapy (NRT) + weekly group cognitive behavioral therapy (CBT)
Trial: 15188360
Drug: Experimental intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental intervention (1-hour session with a nurse educator + monthly telephone counseling for 6 months)
Trial: 15188360
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (attention placebo: 45-minute video presentation about lupus + monthly telephone calls)
Trial: 11457745
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (nifedipine or manidipine) (n=30)
Trial: 3284316
Drug: Intravenous sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sotalol (1.5 mg/kg load followed by 0.008 mg/kg maintenance, mean dose 150 +/‐ 23 mg)
Trial: 3284316
Drug: Oral sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sotalol (mean dose 583 +/‐ 204 mg daily)
Trial: 27352488
Drug: Deep acupuncture
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep acupuncture at Lianquan (CV 23) and Yifeng (TE 17) combined with swallowing training (twice a day, 20 min per treatment)
Trial: 25243955
Drug: Telbivudine (LdT)
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telbivudine (LdT) 600 mg once daily
Trial: 25243955
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no LdT treatment)
Trial: 22895585
Drug: HD-MTX-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-MTX-based chemotherapy
Trial: 20388472
Drug: Qingshen Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingshen Granule (1 dosage each time, 3 times a day for one month)
Trial: 11850136
Drug: Classroom‐centered (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classroom‐centered (CC) intervention
Trial: 9012303
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no warming therapy)
Trial: 386388
Drug: Racemic propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic propranolol (high doses)
Trial: 31480866
Drug: Narratives reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narratives reporting Vaccine Adverse Events (VAE) at 35% frequency
Trial: 31480866
Drug: Narratives reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narratives reporting Vaccine Adverse Events (VAE) at 5% frequency
Trial: 26002878
Drug: IDAP Treatment
RxNorm normalized name: tenidap
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDAP Treatment Program
Trial: 23343704
Drug: palmitoylethanolamide (PEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palmitoylethanolamide (PEA) 400 mg and transpolydatin 40 mg
Trial: 17445927
Drug: Cisplatin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (6 mg/m2 i.v. x20, daily before RT) with RT (35 x 2 Gy)
Trial: 17445927
Drug: Hydr‐Ac‐RT Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydr‐Ac‐RT Group (daily i.v. prehydration and accelerated RT)
Trial: 2568792
Drug: Ionic monomeric
RxNorm normalized name: Monoferric
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic monomeric preparation
Trial: 2568792
Drug: Nonionic monomeric
RxNorm normalized name: Monoferric
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic monomeric preparation
Trial: 1014119
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone
Trial: 1014119
Drug: Alcohol infusion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol infusion of the pituitary
Trial: 23706959
Drug: Restrictive RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive RBC transfusion policy (hemoglobin <8 g/dL)
Trial: 23706959
Drug: Liberal RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal RBC transfusion policy (hemoglobin <10 g/dL)
Trial: 15224295
Drug: Gamma-radiation therapy
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-radiation therapy (gamma-RT)
Trial: 11282761
Drug: L-arginine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (0.5 g/10 kg body weight)
Trial: 11282761
Drug: L-arginine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (1.5 g/10 kg body weight/d)
Trial: 7815238
Drug: Lactose-free corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-free corn syrup-based milk formula
Trial: 27773350
Drug: Fluid resuscitation
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid resuscitation based on GEDI (goal-directed therapy until GEDI reached 800 mL/m2)
Trial: 25256125
Drug: Topical hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydrocortisone cream 1% (control group)
Trial: 22948945
Drug: Chitin-glucan (CG)
RxNorm normalized name: Chitin
DrugBank: Chitin (DB15142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitin-glucan (CG) 4.5 g/day
Trial: 22948945
Drug: Chitin-glucan (CG)
RxNorm normalized name: Chitin
DrugBank: Chitin (DB15142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitin-glucan (CG) 1.5 g/day
Trial: 22948945
Drug: Chitin-glucan (CG)
RxNorm normalized name: Chitin
DrugBank: Chitin (DB15142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitin-glucan (CG) 1.5 g/day plus olive oil (OO) extract 135 mg/day
Trial: 16447104
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (ABCD) 7.5 mg/kg (group A)
Trial: 16447104
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (ABCD) 10 mg/kg (group B)
Trial: 16447104
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (ABCD) 15 mg/kg (group C)
Trial: 12903909
Drug: 0.1 mol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mol/l hydrochloric acid instillation
Trial: 10769855
Drug: Midazolam, nalbuphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, nalbuphine, and droperidol administered intravenously, along with nitrous oxide and oxygen by nasal mask.
Trial: 10769855
Drug: Midazolam, nalbuphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, nalbuphine, and droperidol administered intravenously.
Trial: 9069567
Drug: Lower GIR
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower GIR group (insulin resistance)
Trial: 9069567
Drug: Intermediate GIR
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate GIR group (insulin resistance)
Trial: 9069567
Drug: Highest GIR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Highest GIR group (insulin resistance)
Trial: 30600754
Drug: Intravenous 20
RxNorm normalized name: Dantrium Intravenous 20mg Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 20 mg nefopam in 100 mL normal saline before spinal anesthesia
Trial: 30600754
Drug: Placebo: intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: intravenous normal saline 100 mL
Trial: 22055594
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (20mg omeprazole bid, 1000mg amoxicillin bid, 500mg clarithromycin bid for 14 days)
Trial: 22055594
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (20mg omeprazole bid and 1000mg amoxicillin bid for 14 days, 500mg ciprofloxacin bid for the first 7 days, 200mg furazolidone bid for the last 7 days)
Trial: 22055594
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CrCl >90 mg/dl)
Trial: 1329300
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 50 mg thrice daily for 1 week
Trial: 22522357
Drug: Topical MMR
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical MMR vaccine
Trial: 20429049
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (GLU) 0.2 U/kg
Trial: 20429049
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (ASP) 0.2 U/kg
Trial: 12114885
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (n = 103)
Trial: 7593777
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg daily for 12 weeks)
Trial: 7580551
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg daily for 12 weeks)
Trial: 2073105
Drug: Cefprozil 30
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil 30 mg/kg
Trial: 2073105
Drug: Cis isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis isomer 15 mg/kg
Trial: 2073105
Drug: Cis isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis isomer 30 mg/kg
Trial: 2073105
Drug: Trans isomer
RxNorm normalized name: 3-butylidenephthalide, mixture of cis and trans isomers
DrugBank: Butylidenephthalide (DB17259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans isomer 15 mg/kg
Trial: 2073105
Drug: Trans isomer
RxNorm normalized name: 3-butylidenephthalide, mixture of cis and trans isomers
DrugBank: Butylidenephthalide (DB17259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans isomer 30 mg/kg
Trial: 17785486
Drug: In-treatment decrease
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-treatment decrease of Cornell product (continuous variable)
Trial: 17785486
Drug: In-treatment reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-treatment reduction in Cornell product of 236 mm x msec or more
Trial: 16135349
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (IV PCA) with morphine (1.5 mg; lockout interval, 8 min)
Trial: 12297207
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (bean extract)
Trial: 533575
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg antipyrine
Trial: 533575
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg antipyrine
Trial: 533575
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg antipyrine
Trial: 24191873
Drug: Plasma of
RxNorm normalized name: HUMAN IGG POLYCLONAL ANTIBODY DERIVED FROM PLASMA OF TRANSCHROMOSOMAL BOVINE TARGETED TO THE SPIKE PROTEIN OF SARS COV-2
DrugBank: SAB-185 (DB16491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma of argon cleaning treatment
Trial: 23289009
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (daily oral Zn supplements for eight weeks)
Trial: 18976257
Drug: Alpha lipoic
RxNorm normalized name: Alpha Lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha lipoic acid (ALA) 800 mg day(-1) for 8 weeks
Trial: 15124551
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (5-FU-CDDP)
Trial: 15124551
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of the boost from 15 Gy to 25-25 Gy
Trial: 10795929
Drug: Vasopressin V2
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin V2 antagonists
Trial: 10795929
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (fluid restriction and treatment of underlying disorder)
Trial: 1577025
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (20 mg.day‐1)
Trial: 22486134
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg daily for 6 months
Trial: 21138627
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group (without anti-viral therapy)
Trial: 21138627
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received lamivudine therapy)
Trial: 21138627
Drug: Antiviral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral group (HBeAg negative)
Trial: 21138627
Drug: Antiviral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral group (HBeAg positive)
Trial: 21138627
Drug: Antiviral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral group
Trial: 1932377
Drug: Interleukin-1 (IL-1)
RxNorm normalized name: interleukin-1 (IL-1) trap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF) treatment
Trial: 20597558
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate injection plus thumb spica cast
Trial: 16191750
Drug: Nicotine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (20 microg/kg) via nasal spray
Trial: 16191750
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 microg/kg) via nasal spray
Trial: 2321781
Drug: Ilioinguinal/iliohypogastric (IG/IH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilioinguinal/iliohypogastric (IG/IH) nerve block with 0.25 ml/kg of 0.25% bupivacaine
Trial: 2321781
Drug: Instillation nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation nerve block with up to 0.5 ml/kg of 0.25% bupivacaine
Trial: 91434
Drug: cis-platinum, vinblastine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-platinum, vinblastine, and bleomycin combination chemotherapy
Trial: 28052291
Drug: Yogurt containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt containing Lactobacillus gasseri OLL2716 (LG), 112 ml twice daily for 6 weeks
Trial: 28052291
Drug: Placebo yogurt,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo yogurt, 112 ml twice daily for 6 weeks
Trial: 21593577
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention (systemic corticosteroid for 2 weeks, inhaled corticosteroid for 16 weeks, bronchodilator(s))
Trial: 21593577
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (current asthma treatment guidelines for 18 weeks)
Trial: 17565246
Drug: Radiotherapy (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (doses more than 60 Gy) in post menopausal cases
Trial: 17565246
Drug: Breast irradiation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast irradiation with concurrent chemotherapy
Trial: 17565246
Drug: Chemotherapy first
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy first before irradiation
Trial: 14748938
Drug: Lutein, beta-carotene,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein, beta-carotene, or lycopene (natural isolate capsules, 15 mg/d, 4 weeks)
Trial: 14748938
Drug: Lycopene or
RxNorm normalized name: lycopene Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene or lutein (>2.00 micromol/l)
Trial: 14748938
Drug: Carotenoids (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotenoids (0.50 to 1.00 micromol/l)
Trial: 11240091
Drug: Single global
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single global assessment of treatment efficacy (5-point scale)
Trial: 14715393
Drug: Aspirin 600/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600/650 mg
Trial: 11180023
Drug: Rofecoxib 12.5
RxNorm normalized name: rofecoxib 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 12.5 mg, 25 mg, 50 mg
Trial: 8742572
Drug: Acarbose (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (300 mg/daily)
Trial: 8742572
Drug: Metformin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,500 mg/daily)
Trial: 31427334
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose lowering drugs (OGLDs) starting with metformin and supplemented as needed with glibenclamide.
Trial: 31427334
Drug: Insulin therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin therapy.
Trial: 27393274
Drug: Chemoembolization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoembolization with TANDEM™ loaded with 150 mg of doxorubicin
Trial: 27393274
Drug: Chemoembolization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoembolization with TANDEM™ loaded with 100 mg of doxorubicin
Trial: 27393274
Drug: High loading
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High loading group (150 mg doxorubicin)
Trial: 21319602
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency (PRF) therapy
Trial: 21319602
Drug: Electro-acupuncture (EA)
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture (EA) therapy
Trial: 18379478
Drug: Afobazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afobazole (30 to 60 mg daily, mean 50 mg) for 6 weeks
Trial: 16081755
Drug: Custom made
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custom made mouthguard (MG)
Trial: 11851576
Drug: Raloxifene (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (both doses) in subset with increased cardiovascular risk
Trial: 10209802
Drug: estradiol-noretisteron acetate
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol-noretisteron acetate treatment
Trial: 7797785
Drug: 800 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 micrograms of inhaled triamcinolone once daily at 3:00 PM (QD group)
Trial: 7797785
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of inhaled triamcinolone four times a day (QID group)
Trial: 23131574
Drug: Nonprotein calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonprotein calorie (NPC) supplement (200-kcal daily)
Trial: 21439167
Drug: Supralingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supralingual immunotherapy